Crofelemer powder

05/28/26 — Jaguar Health posted a press-release listing that includes an item titled “Jaguar Health Research in Ethnobotanical Medicine Helps Advance Crofelemer Development for Genetically Defined Rare Congenital Gastrointestinal Disorders.” The provided page content does not include the body of the release, so no specific study design, clinical-trial details, quantitative results, regulatory interactions, or timelines can be confirmed from the HTML/text shown.

Business/clinical significance (based only on the title and context on the press-release index): Jaguar is positioning crofelemer development toward genetically defined, rare congenital gastrointestinal disorders, implying a rare-disease R&D focus, but the page excerpt provides no substantiating data or milestones beyond the headline.